11/18
07:00 am
eypt
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/11
08:09 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $30.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $30.00 to $22.00. They now have a "buy" rating on the stock.
11/11
08:09 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $38.00 to $33.00. They now have an "outperform" rating on the stock.
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $38.00 to $33.00. They now have an "outperform" rating on the stock.
11/8
05:40 pm
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Chardan Capital from $28.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Chardan Capital from $28.00 to $33.00. They now have a "buy" rating on the stock.
11/7
10:32 am
eypt
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
07:00 am
eypt
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Medium
Report
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
11/5
05:35 am
eypt
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing [Yahoo! Finance]
Low
Report
With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing [Yahoo! Finance]
11/4
07:00 am
eypt
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Low
Report
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
10/31
04:00 pm
eypt
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Low
Report
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
10/29
09:47 pm
eypt
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
Low
Report
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
10/29
08:00 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
10/28
05:14 pm
eypt
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Low
Report
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
10/28
07:00 am
eypt
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
High
Report
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
10/25
08:37 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/24
07:00 am
eypt
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
Medium
Report
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
10/16
08:44 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
High
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/16
07:00 am
eypt
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/21
02:32 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.
9/16
07:00 am
eypt
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/5
02:03 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.
9/4
07:00 am
eypt
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Low
Report
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
8/29
07:13 pm
eypt
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) [Seeking Alpha]
Low
Report
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) [Seeking Alpha]
8/28
08:33 am
eypt
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
Medium
Report
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
8/27
07:00 am
eypt
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Low
Report
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences